Mount Sinai Medical Center

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Lunedì, Aprile 29, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, PFS, Congress, Pfizer, Peripheral neuropathy, Priority review, Risk, Woman, Food, Progression-free survival, Nausea, Survival, Death, Pneumonitis, Hazard, ESMO, Gynecologic Oncology (journal), OS, Disease, ADC, Patient, PFE, Bleeding, Fatigue, Toxicity, Diagnosis, Constipation, Clinical trial, Mount Sinai Medical Center, Cervical cancer, Nosebleed, Pharmaceutical industry

This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval.

Key Points: 
  • This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval.
  • TIVDAK is the first antibody-drug conjugate (ADC) with demonstrated overall survival data to be granted full FDA approval in this patient population.
  • The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial ( NCT04697628 ), in which TIVDAK met its primary endpoint of overall survival (OS) in patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy.
  • “Treatment options for patients with advanced or recurrent cervical cancer are limited.

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Lunedì, Aprile 29, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, PFS, Congress, Pfizer, Peripheral neuropathy, Priority review, Risk, Woman, Food, Progression-free survival, Nausea, Survival, Death, Pneumonitis, ESMO, Gynecologic Oncology (journal), OS, Disease, Patient, PFE, Bleeding, Fatigue, Toxicity, Constipation, Diagnosis, Inc., Clinical trial, Mount Sinai Medical Center, Cervical cancer, Nosebleed, Pharmaceutical industry

"Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease, and patients are in need of survival-extending treatment options,” said Chris Boshoff, M.D., Ph.D., Chief Oncology Officer, Executive Vice President at Pfizer.

Key Points: 
  • "Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease, and patients are in need of survival-extending treatment options,” said Chris Boshoff, M.D., Ph.D., Chief Oncology Officer, Executive Vice President at Pfizer.
  • Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate (ORR) were also met.
  • Median OS for patients treated with TIVDAK was 11.5 months [95% CI: 9.8-14.9] versus chemotherapy 9.5 months [95% CI: 7.9-10.7].
  • “Treatment options for patients with advanced or recurrent cervical cancer are limited.

GTG to pilot GeneType in Breast Screen centers across the U.S.

Retrieved on: 
Giovedì, Aprile 11, 2024
Breast cancer, Breast, GTG, Risk, Woman, Montefiore Medical Center, Health, Radar, Florida International University, Communication, ASX, FACS, Patient, Medicine, Breast cancer screening, Risk assessment, Mount Sinai Medical Center, FACOG, Medical imaging

The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented.

Key Points: 
  • The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented.
  • Risk-stratified Decision-Making: By integrating the geneType Breast Cancer Risk Assessment Test into breast imaging centers, patients at higher risk of breast cancer can be easily identified during imaging appointments.
  • Implementation of GeneType: Collaborating with leading breast imaging centers will provide an excellent opportunity for integrating geneType in a high throughput clinical scenario.
  • Its integration into breast imaging centers marks a significant shift in how breast cancer risk is evaluated.

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Retrieved on: 
Giovedì, Febbraio 15, 2024
Therapy, Acquisition, Gilead Sciences, Immunotherapy, University of the Witwatersrand, Johnson & Johnson, Pleasure, NewYork-Presbyterian Hospital, Lead, University, Patient, Anat, Mount Sinai Medical Center, Drug, Compugen, Pharmaceutical industry

HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.

Key Points: 
  • HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.
  • Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.
  • "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.
  • Michelle obtained her medical degree from University of the Witwatersrand, South Africa and is a board-certified pediatric hematologist and oncologist.

The Inner Circle Acknowledges, Paul V. Sunkavalli as a Pinnacle Lifetime Member

Retrieved on: 
Lunedì, Febbraio 12, 2024
Philosophy, Mary, mother of Jesus, Hackensack Meridian Health, College, Inner circle, Chemistry, Education, Spartan Health Sciences University, Saint Mary's College, University, Patient, Family, Mount Sinai Medical Center, ADHD, Child, Trust, Biology, Spectrum, Baylor University, Physician, Hindu temple, Partnership, Nursing

MANAHAWKIN, N.J., Feb. 12, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Paul V. Sunkavalli is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Pediatrics.

Key Points: 
  • MANAHAWKIN, N.J., Feb. 12, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Paul V. Sunkavalli is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Pediatrics.
  • Dr. Sunkavalli pursued higher education at St. Mary's College where he earned a double major in biology and chemistry after transferring from Baylor University.
  • He received a Doctor of Medicine degree from Spartan Health Sciences University in St. Lucia; completed a Pediatric residency at Mount Sinai Medical Center (Jersey City Program).
  • Dr. Sunkavalli asserts that he is inspired by his entire family, including his father, Dr. Krishna Sunkavalli and his wife Dr. Anupama Sunkavalli.

Mount Sinai Medical Center First to Utilize AI Technology to Treat Complex Aortic Conditions at South Florida's Only Aortic Center

Retrieved on: 
Lunedì, Febbraio 12, 2024
MIAMI, Aneurysm, Cardiology, Surgeon, Radiation, Risk, Health, Patient, Mount Sinai Medical Center, Map, Disease, Medtronic, Interview, Software, Medical device

MIAMI BEACH, Fla., Feb. 8, 2024 /PRNewswire/ -- Mount Sinai Medical Center is proud to announce the implementation of unique AI software designed to support the treatment of patients with complex aortic disease.

Key Points: 
  • MIAMI BEACH, Fla., Feb. 8, 2024 /PRNewswire/ -- Mount Sinai Medical Center is proud to announce the implementation of unique AI software designed to support the treatment of patients with complex aortic disease.
  • As part of a collaboration between Cydar Medical and Medtronic, this software employs state-of-the-art minimally invasive endovascular technology that is being used by surgeons at Mount Sinai's Aortic Center.
  • The medical center currently stands as the first and only institution to use this technology in all of Eastern Florida.
  • "We are thrilled a medical center as renowned and respected as Mount Sinai has implemented our product into their clinical work," says Paul Mussenden, the CEO at Cydar Medical.

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Giovedì, Febbraio 1, 2024
Principal, Public key certificate, Cordis, MD, Society, FDA, Columbia University, International Society, Book, Family, American Academy, Cataract, Don, Lehigh University, Culture, University, Refraction, ASCRS, Refractive surgery, Growth, American College, Mount Sinai Medical Center, Publication, Wills Eye Hospital, CFO, Congress, Therapy, Eye surgery, MBA, Executive, Accounting

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.

Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry

Retrieved on: 
Giovedì, Novembre 16, 2023
TAVR, Safety, NYSE, TFX, Cardiology, Structural heart disease, Patient, Registry, Interventional cardiology, Intervention, Hemostasis, SAFE, Teleflex, Doctor of Philosophy, Mount Sinai Medical Center, VCD, Mount Sinai Hospital (Manhattan), Medical device, Medical imaging, Hospital, Surgery, MD

The registry will include appropriate patient selection and proper vascular access.

Key Points: 
  • The registry will include appropriate patient selection and proper vascular access.
  • Enrolling at least 250 patients in up to 15 major TAVR institutions across the US and Canada, the ACCESS-MANTA™ Registry is an international, multicenter, prospective, observational, single-arm clinical registry.
  • “Large bore access site complications are recognized as morbid,1 driving increased costs and prolonged length-of-stay,2” said Teleflex Interventional Medical Director, Christopher Buller, MD.
  • “We are excited that Mount Sinai Medical Center is spearheading the Teleflex ACCESS-MANTA™ Registry,” said Dr. Khera, Co-Global Principal Investigator.

ObservSMART Extends Service to Include Mount Sinai Medical Center's Emergency Centers

Retrieved on: 
Lunedì, Dicembre 11, 2023
Jay, Mount Sinai Medical Center, Health, Observation, Hospital, Patient, Patient safety, Partnership, Nursing

ObservSMART is enjoying a partnership with Mount Sinai Medical Center and is looking forward to ensuring patient safety.

Key Points: 
  • ObservSMART is enjoying a partnership with Mount Sinai Medical Center and is looking forward to ensuring patient safety.
  • The Jay and Jeanie Schottenstien Center for Behavioral Health Department plays an essential role in Mount Sinai Medical Center's mission to provide high quality health care to our diverse community.
  • By incorporating ObservSMART into the behavioral health and emergency centers, Mount Sinai's continues their commitment to enhancing patient safety and the level of personalized care each patient receives.
  • The continued collaboration between Mount Sinai and ObservSMART highlights a focus on quality improvement, driven by healthcare innovation, data-driven insights, and a joint dedication to enhancing both staff and patient safety.

Seventy-One Percent of Persons With Type 2 Diabetes Say a Remote Patient Monitoring (RPM) Program Would Help Them Better Manage Their Health

Retrieved on: 
Venerdì, Novembre 10, 2023
Technology, Medical Devices, Diabetes, Health Technology, Telemedicine, Virtual Medicine, Software, Managed Care, Health, Data Management, RPM, Patient, Mount Sinai Medical Center, Reading, Physician, MD, Doctor of Philosophy, Research, Disease, CDE, Type 2 diabetes, Medicine, Type 2, Smart meter, Hospital, AT&T, Glucose, Pharmaceutical industry, Medical device

For the same question in the 2021 Diabetes Care Survey, only 35 percent of the respondents indicated that an RPM program would better help them manage their diabetes.

Key Points: 
  • For the same question in the 2021 Diabetes Care Survey, only 35 percent of the respondents indicated that an RPM program would better help them manage their diabetes.
  • The dramatic increase shows a rise in the awareness, ease of use, and effectiveness of a cellular remote glucose monitoring program.
  • The convenience of cellular-based glucose monitors enables better patient adherence to care plan instructions, leading to stabilized or improved outcomes.
  • With cellular-enabled remote glucose monitoring solutions from Smart Meter, providers are assured of getting the latest and most accurate data when a patient tests.